[
  {
    "ts": null,
    "headline": "Pfizer Inc (PFE) Q4 2025 Earnings Call Highlights: Strategic Acquisitions and Revenue Guidance ...",
    "summary": "Despite a decline in COVID-19 product revenues, Pfizer Inc (PFE) expands gross margins and outlines transformative growth strategies for 2026.",
    "url": "https://finnhub.io/api/news?id=f5d81dba6254721acbc70af3cc13a661038967114cc1c866886ffb674886d454",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770152615,
      "headline": "Pfizer Inc (PFE) Q4 2025 Earnings Call Highlights: Strategic Acquisitions and Revenue Guidance ...",
      "id": 138347242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Despite a decline in COVID-19 product revenues, Pfizer Inc (PFE) expands gross margins and outlines transformative growth strategies for 2026.",
      "url": "https://finnhub.io/api/news?id=f5d81dba6254721acbc70af3cc13a661038967114cc1c866886ffb674886d454"
    }
  },
  {
    "ts": null,
    "headline": "These Are The Worst 25 Stocks to Own in February",
    "summary": "Biogen stock tends to disappoint in February",
    "url": "https://finnhub.io/api/news?id=4ea5354df6101b8335eae9361e6c50048afe8d2d0303349a30e64ba88dde8e64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770148649,
      "headline": "These Are The Worst 25 Stocks to Own in February",
      "id": 138345699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Biogen stock tends to disappoint in February",
      "url": "https://finnhub.io/api/news?id=4ea5354df6101b8335eae9361e6c50048afe8d2d0303349a30e64ba88dde8e64"
    }
  },
  {
    "ts": null,
    "headline": "Obesity Drug Bets Get a Reality Check—but Investors Shouldn’t Panic",
    "summary": "Novo Nordisk pre-announced weaker-than-expected guidance, forecasting a 5% to 13% decline in constant-currency sales this year, citing pricing pressure and intensifying competition.  Earlier Tuesday, Pfizer reported underwhelming data for its once-monthly obesity injection, raising fresh doubts about the Metsera acquisition it announced last year, and whether it will be enough to support a blockbuster competitor to the Lilly and Novo injections.  Pfizer shares fell 3.2%, while Novo Nordisk’s American depositary receipts plunged 15%.",
    "url": "https://finnhub.io/api/news?id=4e3a3867cd2a9be5301e0b0e447bd68f31a093fc277bb8c5499383a9b8f64eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770148121,
      "headline": "Obesity Drug Bets Get a Reality Check—but Investors Shouldn’t Panic",
      "id": 138347127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo Nordisk pre-announced weaker-than-expected guidance, forecasting a 5% to 13% decline in constant-currency sales this year, citing pricing pressure and intensifying competition.  Earlier Tuesday, Pfizer reported underwhelming data for its once-monthly obesity injection, raising fresh doubts about the Metsera acquisition it announced last year, and whether it will be enough to support a blockbuster competitor to the Lilly and Novo injections.  Pfizer shares fell 3.2%, while Novo Nordisk’s American depositary receipts plunged 15%.",
      "url": "https://finnhub.io/api/news?id=4e3a3867cd2a9be5301e0b0e447bd68f31a093fc277bb8c5499383a9b8f64eeb"
    }
  },
  {
    "ts": null,
    "headline": "Stock market today: Dow, Nasdaq, S&P 500 sink as tech falters amid flood of earnings",
    "summary": "Stocks are leaning higher following a strong start to February trade.",
    "url": "https://finnhub.io/api/news?id=17ac8e4ee9280d36440b1ab79d9a814eb658cd852c1518fa96b1b48e9bc56159",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770146669,
      "headline": "Stock market today: Dow, Nasdaq, S&P 500 sink as tech falters amid flood of earnings",
      "id": 138345457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stocks are leaning higher following a strong start to February trade.",
      "url": "https://finnhub.io/api/news?id=17ac8e4ee9280d36440b1ab79d9a814eb658cd852c1518fa96b1b48e9bc56159"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO",
    "summary": "Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its top and bottom lines. The stock is coming under some pressure on Tuesday despite the positive earnings release. Pfizer chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about Pfizer's timeline for a GLP-1 obesity drug and the company's other pharmaceutical products in its pipeline, especially after acquiring Metsera in November 2025. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=b1167ce2acedb7f9a44b1362bc2c1673ef104cd31521f9952ac6dc0863c7122e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770145575,
      "headline": "Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO",
      "id": 138345675,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its top and bottom lines. The stock is coming under some pressure on Tuesday despite the positive earnings release. Pfizer chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about Pfizer's timeline for a GLP-1 obesity drug and the company's other pharmaceutical products in its pipeline, especially after acquiring Metsera in November 2025. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=b1167ce2acedb7f9a44b1362bc2c1673ef104cd31521f9952ac6dc0863c7122e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer sets sights on R&D strategy amid modest FY25 results",
    "summary": "As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.",
    "url": "https://finnhub.io/api/news?id=61944ef22c371dab2afb526135b1dcf6f4c0c08677d124a3eeb427845667e4f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770145167,
      "headline": "Pfizer sets sights on R&D strategy amid modest FY25 results",
      "id": 138345676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.",
      "url": "https://finnhub.io/api/news?id=61944ef22c371dab2afb526135b1dcf6f4c0c08677d124a3eeb427845667e4f6"
    }
  },
  {
    "ts": null,
    "headline": "Stock market today: Nasdaq, S&P 500 slide as investors digest flood of tech earnings, government shutdown",
    "summary": "Stocks are leaning higher following a strong start to February trade.",
    "url": "https://finnhub.io/api/news?id=4e134790a16684e7be9c4fa2143cce4a02687063eaa645b1cab6b84dfac21a66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770140007,
      "headline": "Stock market today: Nasdaq, S&P 500 slide as investors digest flood of tech earnings, government shutdown",
      "id": 138343974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stocks are leaning higher following a strong start to February trade.",
      "url": "https://finnhub.io/api/news?id=4e134790a16684e7be9c4fa2143cce4a02687063eaa645b1cab6b84dfac21a66"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Releases Early Obesity Data Showing Up to 12.3% Weight Loss",
    "summary": "The drugmaker shared limited early results from a Metsera obesity treatment as investors weigh its $10 billion acquisition and declining Covid sales.",
    "url": "https://finnhub.io/api/news?id=00b159e83422e4b048819f1ff4f0c70f3eb986c3fec0c19f56392a41faa6df8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770139347,
      "headline": "Pfizer Releases Early Obesity Data Showing Up to 12.3% Weight Loss",
      "id": 138344220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The drugmaker shared limited early results from a Metsera obesity treatment as investors weigh its $10 billion acquisition and declining Covid sales.",
      "url": "https://finnhub.io/api/news?id=00b159e83422e4b048819f1ff4f0c70f3eb986c3fec0c19f56392a41faa6df8b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge",
    "summary": "Pfizer's (PFE) fourth-quarter earnings unexpectedly increased year over year, although the pharmaceu",
    "url": "https://finnhub.io/api/news?id=eaf3b0320346d4f9af0f8bbf540845a0aa1ac9a6ea70b6e423a04c3c6df20fb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138907,
      "headline": "Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge",
      "id": 138344070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's (PFE) fourth-quarter earnings unexpectedly increased year over year, although the pharmaceu",
      "url": "https://finnhub.io/api/news?id=eaf3b0320346d4f9af0f8bbf540845a0aa1ac9a6ea70b6e423a04c3c6df20fb4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight",
    "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
    "url": "https://finnhub.io/api/news?id=953b8a82a1d8001b11b9c5d344aa9550a048c331cdd4bbfae58b2d9288dbc8ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138322,
      "headline": "Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight",
      "id": 138344071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
      "url": "https://finnhub.io/api/news?id=953b8a82a1d8001b11b9c5d344aa9550a048c331cdd4bbfae58b2d9288dbc8ed"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Q4 2025 Earnings Call Transcript",
    "summary": "Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments.  If successful, we will substantially expand the US addressable population with approximately 22,500 additional patients across both cis-eligible and cis-ineligible muscle-invasive bladder cancer, up from about 19,000 patients in metastatic urothelial cancer.",
    "url": "https://finnhub.io/api/news?id=b749871217aa1b4a189311c35baba0a5069fdb852c587c44035d07016590436e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770137056,
      "headline": "Pfizer (PFE) Q4 2025 Earnings Call Transcript",
      "id": 138344223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments.  If successful, we will substantially expand the US addressable population with approximately 22,500 additional patients across both cis-eligible and cis-ineligible muscle-invasive bladder cancer, up from about 19,000 patients in metastatic urothelial cancer.",
      "url": "https://finnhub.io/api/news?id=b749871217aa1b4a189311c35baba0a5069fdb852c587c44035d07016590436e"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: PayPal Misses Q4 Estimates, Names CEO; Palantir Shares Rise on Strong Results",
    "summary": "US benchmark stock indexes fell in late-morning trading Tuesday as investors weighed earnings from m",
    "url": "https://finnhub.io/api/news?id=0888a5e63c2bc01e9bb9169b8905c0be0c52d5c10800919507ec57cf2ffec643",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136850,
      "headline": "Top Midday Stories: PayPal Misses Q4 Estimates, Names CEO; Palantir Shares Rise on Strong Results",
      "id": 138344108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US benchmark stock indexes fell in late-morning trading Tuesday as investors weighed earnings from m",
      "url": "https://finnhub.io/api/news?id=0888a5e63c2bc01e9bb9169b8905c0be0c52d5c10800919507ec57cf2ffec643"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer Stock Dropped Today",
    "summary": "Is Pfizer stock a buy at under 9x earnings? Yes. It is.",
    "url": "https://finnhub.io/api/news?id=610b58f9818f95aa01eaeb57c8be3f1d7ac6c367000fb660b1ec36a7f0341a56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136617,
      "headline": "Why Pfizer Stock Dropped Today",
      "id": 138344225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Is Pfizer stock a buy at under 9x earnings? Yes. It is.",
      "url": "https://finnhub.io/api/news?id=610b58f9818f95aa01eaeb57c8be3f1d7ac6c367000fb660b1ec36a7f0341a56"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data",
    "summary": "PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.",
    "url": "https://finnhub.io/api/news?id=32b36462779a19e3d05eb7619b1f5e0030dbbdc28fbbd5c806738eb5686b691e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136320,
      "headline": "Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data",
      "id": 138345545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.",
      "url": "https://finnhub.io/api/news?id=32b36462779a19e3d05eb7619b1f5e0030dbbdc28fbbd5c806738eb5686b691e"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Pfizer Stock Sliding Today",
    "summary": "Pfizer Reports Net Loss; Weight-Loss Drug Shows Early Promise",
    "url": "https://finnhub.io/api/news?id=ad62cd46fd13d9fee6974957c7d598fb3a74211c5d424cb571cf9ae12a2c40b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136226,
      "headline": "Why Is Pfizer Stock Sliding Today",
      "id": 138344226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Reports Net Loss; Weight-Loss Drug Shows Early Promise",
      "url": "https://finnhub.io/api/news?id=ad62cd46fd13d9fee6974957c7d598fb3a74211c5d424cb571cf9ae12a2c40b7"
    }
  },
  {
    "ts": null,
    "headline": "Market Awaits JOLTS Jobs Report",
    "summary": "Market Awaits JOLTS Jobs Report.",
    "url": "https://finnhub.io/api/news?id=cb5a39d86ad7e4bed95ffa3fc4762ac20a7bf68aac285a0c5a4e0876abda66df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770134400,
      "headline": "Market Awaits JOLTS Jobs Report",
      "id": 138344141,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Market Awaits JOLTS Jobs Report.",
      "url": "https://finnhub.io/api/news?id=cb5a39d86ad7e4bed95ffa3fc4762ac20a7bf68aac285a0c5a4e0876abda66df"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer shares drop on quarterly loss",
    "summary": "Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues.\"Current financial guidance does not anticipate any share repurchases in 2026,\" said Pfizer, which anticipates research and development expenses of between $10.5 and $11.5 billion in 2026.",
    "url": "https://finnhub.io/api/news?id=b34108fcd631428855146344d17974c1a97f338e41933d30c5b865b5c229d94f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770133705,
      "headline": "Pfizer shares drop on quarterly loss",
      "id": 138342680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues.\"Current financial guidance does not anticipate any share repurchases in 2026,\" said Pfizer, which anticipates research and development expenses of between $10.5 and $11.5 billion in 2026.",
      "url": "https://finnhub.io/api/news?id=b34108fcd631428855146344d17974c1a97f338e41933d30c5b865b5c229d94f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh",
    "summary": "Despite strong Q4 earnings, the pharma giant braces for $1.5B impact from expiring exclusivities.",
    "url": "https://finnhub.io/api/news?id=ab5edd37d5756c514034157b311fc306e727e7eab7a93cb28555fc8eceade22e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770132917,
      "headline": "Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh",
      "id": 138342681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Despite strong Q4 earnings, the pharma giant braces for $1.5B impact from expiring exclusivities.",
      "url": "https://finnhub.io/api/news?id=ab5edd37d5756c514034157b311fc306e727e7eab7a93cb28555fc8eceade22e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Drops On Obesity-Drug Study Data",
    "summary": "Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war last year.  The company said the injected drug, PF’3944, helped people lose 12.3% of their body weight versus a placebo after 28 weeks of treatment in a mid-stage clinical trial.  Analysts said the drug’s efficacy was slightly inferior to Eli Lilly’s Zepbound weight-loss drug, and raised concerns about study subjects discontinuing treatment due to side effects.",
    "url": "https://finnhub.io/api/news?id=159db082a43241e4ae26bb3bf8c11188f7149f54d278d4d507ebf47e0a127b4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770132743,
      "headline": "Pfizer Stock Drops On Obesity-Drug Study Data",
      "id": 138344073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war last year.  The company said the injected drug, PF’3944, helped people lose 12.3% of their body weight versus a placebo after 28 weeks of treatment in a mid-stage clinical trial.  Analysts said the drug’s efficacy was slightly inferior to Eli Lilly’s Zepbound weight-loss drug, and raised concerns about study subjects discontinuing treatment due to side effects.",
      "url": "https://finnhub.io/api/news?id=159db082a43241e4ae26bb3bf8c11188f7149f54d278d4d507ebf47e0a127b4c"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings, JOLTS & a Changing of the Disney Guard",
    "summary": "Disney CEO Bob Iger will step down next month -- not the end of the year, as earlier surmised.",
    "url": "https://finnhub.io/api/news?id=5c737a1b699b4ee77bd51b01cdcdb9e522430d0ad425a678e231536f59044fae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770132360,
      "headline": "Q4 Earnings, JOLTS & a Changing of the Disney Guard",
      "id": 138344142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Disney CEO Bob Iger will step down next month -- not the end of the year, as earlier surmised.",
      "url": "https://finnhub.io/api/news?id=5c737a1b699b4ee77bd51b01cdcdb9e522430d0ad425a678e231536f59044fae"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript",
    "summary": "Pfizer Inc. (PFE) Q4 2025 Earnings Call February 3, 2026 10:00 AM ESTCompany ParticipantsFrancesca DeMartino - Chief Investor Relations OfficerAlbert Bourla...",
    "url": "https://finnhub.io/api/news?id=ce6a4386cefa7bddfe094192024cee7ec504fcbe9c397a4e5ed62e8f4d8c2b35",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770130830,
      "headline": "Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript",
      "id": 138345925,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. (PFE) Q4 2025 Earnings Call February 3, 2026 10:00 AM ESTCompany ParticipantsFrancesca DeMartino - Chief Investor Relations OfficerAlbert Bourla...",
      "url": "https://finnhub.io/api/news?id=ce6a4386cefa7bddfe094192024cee7ec504fcbe9c397a4e5ed62e8f4d8c2b35"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Targets Monthly Obesity Shot. Why Lilly Could Still Have The Weight-Loss Heavyweight.",
    "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
    "url": "https://finnhub.io/api/news?id=2f121d6b13b77d97de82cb16d13778897921668c5b4b22e8d487318fdc262550",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770130779,
      "headline": "Pfizer Targets Monthly Obesity Shot. Why Lilly Could Still Have The Weight-Loss Heavyweight.",
      "id": 138342544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
      "url": "https://finnhub.io/api/news?id=2f121d6b13b77d97de82cb16d13778897921668c5b4b22e8d487318fdc262550"
    }
  },
  {
    "ts": null,
    "headline": "Stock market today: Nasdaq, S&P 500 fall as investors digest flood of tech earnings, partial government shutdown",
    "summary": "Stocks are leaning higher following a strong start to February trade.",
    "url": "https://finnhub.io/api/news?id=6526d3edc7de3275dafc13cc6ae64e9fdb3c4cb40ba054910da98c4b97e4fced",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770129374,
      "headline": "Stock market today: Nasdaq, S&P 500 fall as investors digest flood of tech earnings, partial government shutdown",
      "id": 138342461,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stocks are leaning higher following a strong start to February trade.",
      "url": "https://finnhub.io/api/news?id=6526d3edc7de3275dafc13cc6ae64e9fdb3c4cb40ba054910da98c4b97e4fced"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=2d577269ada9067c88410cf9d7bc09faa08b86012051ca1285ee31d2f9f3bdc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770129003,
      "headline": "Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 138344230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=2d577269ada9067c88410cf9d7bc09faa08b86012051ca1285ee31d2f9f3bdc6"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Earnings Deluge Continues",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3%, and the actively tra",
    "url": "https://finnhub.io/api/news?id=da212ca83c3f3bc55ace221b03a142f7043b9aba3ee5be87bad7f7bf17e2b3ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770128935,
      "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Earnings Deluge Continues",
      "id": 138342525,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3%, and the actively tra",
      "url": "https://finnhub.io/api/news?id=da212ca83c3f3bc55ace221b03a142f7043b9aba3ee5be87bad7f7bf17e2b3ce"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Messy Q4 Earnings Mask An Improving Business",
    "summary": "Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.",
    "url": "https://finnhub.io/api/news?id=d35b5f6efcdfd74537a4380fb1cdfc64300a2eb6f057c7f117ef2a0e25c3daf3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127379,
      "headline": "Pfizer: Messy Q4 Earnings Mask An Improving Business",
      "id": 138345061,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.",
      "url": "https://finnhub.io/api/news?id=d35b5f6efcdfd74537a4380fb1cdfc64300a2eb6f057c7f117ef2a0e25c3daf3"
    }
  },
  {
    "ts": null,
    "headline": "NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer",
    "summary": "The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.",
    "url": "https://finnhub.io/api/news?id=f9009a5a2c95ef8fb7412da8100ed45d69b87bff99dcce6d89d9416d61569e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770126900,
      "headline": "NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer",
      "id": 138341731,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.",
      "url": "https://finnhub.io/api/news?id=f9009a5a2c95ef8fb7412da8100ed45d69b87bff99dcce6d89d9416d61569e4a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.",
    "summary": "Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.",
    "url": "https://finnhub.io/api/news?id=3832aa262b018c21df2084ae086538ca8e2b17cf52cdc851cda9f65af35475e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770126600,
      "headline": "Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.",
      "id": 138341732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.",
      "url": "https://finnhub.io/api/news?id=3832aa262b018c21df2084ae086538ca8e2b17cf52cdc851cda9f65af35475e1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update",
    "summary": "Pfizer stock tumbled early Tuesday after the drugmaker reaffirmed its modest outlook for 2026 and provided an obesity update.",
    "url": "https://finnhub.io/api/news?id=fa8ff6d6b17f55c5f912acfdefdb87280049315c6dbf9af714f5471c22f63506",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770126083,
      "headline": "Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update",
      "id": 138341733,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer stock tumbled early Tuesday after the drugmaker reaffirmed its modest outlook for 2026 and provided an obesity update.",
      "url": "https://finnhub.io/api/news?id=fa8ff6d6b17f55c5f912acfdefdb87280049315c6dbf9af714f5471c22f63506"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: PayPal Plunges As It Ousts CEO",
    "summary": "PayPal ousts CEO Alex Chris, poaches HP top boss Enrique Lores. Disney names Josh DâAmaro as Igerâs successor. SpaceX-xAI sparks debate over deeper Tesla integration.",
    "url": "https://finnhub.io/api/news?id=0b3a4cf57025c715bb500c55368843ee1c2695e4d5f4dce044608895b04c731d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125358,
      "headline": "Wall Street Lunch: PayPal Plunges As It Ousts CEO",
      "id": 138344873,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2191007168/image_2191007168.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "PayPal ousts CEO Alex Chris, poaches HP top boss Enrique Lores. Disney names Josh DâAmaro as Igerâs successor. SpaceX-xAI sparks debate over deeper Tesla integration.",
      "url": "https://finnhub.io/api/news?id=0b3a4cf57025c715bb500c55368843ee1c2695e4d5f4dce044608895b04c731d"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Pfizer decline vs the broader market as results released",
    "summary": "The pharma industry is handling big transitions, as highlighted in Merck's and Pfizer's earnings, released Tuesday",
    "url": "https://finnhub.io/api/news?id=ba9f79f6434ff1155a2187d85c1256ef9bbfe8bd6c750cd1c983093ef72793f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770124780,
      "headline": "Merck and Pfizer decline vs the broader market as results released",
      "id": 138341659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma industry is handling big transitions, as highlighted in Merck's and Pfizer's earnings, released Tuesday",
      "url": "https://finnhub.io/api/news?id=ba9f79f6434ff1155a2187d85c1256ef9bbfe8bd6c750cd1c983093ef72793f1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates",
    "summary": "Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=9d3412cf1f97fcd857701b290538dd982048dcca4a7d2f23d815ed76f8155134",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770123302,
      "headline": "Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates",
      "id": 138342565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=9d3412cf1f97fcd857701b290538dd982048dcca4a7d2f23d815ed76f8155134"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer backs 2026 outlook amid swing to fourth quarter loss",
    "summary": "Pfizer backs 2026 outlook amid swing to fourth quarter loss",
    "url": "https://finnhub.io/api/news?id=e3591344981cb326f556bb4254c8727d62b05f59a2e5e243883c7b678e09fc49",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121907,
      "headline": "Pfizer backs 2026 outlook amid swing to fourth quarter loss",
      "id": 138341095,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e3591344981cb326f556bb4254c8727d62b05f59a2e5e243883c7b678e09fc49"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Expresses Concern About Pfizer Despite Its “Terrific Yield”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s recent game plan. Cramer had mixed feelings about the stock, as he stated: On the other hand, I worry about Pfizer because while its stock has a terrific yield, I haven’t seen anything of late that would make me feel there’s a new blockbuster […]",
    "url": "https://finnhub.io/api/news?id=46af441c0f628e751bb503aba442b3271c5e5d6e32de5e8600b7c315e5b59c4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121441,
      "headline": "Jim Cramer Expresses Concern About Pfizer Despite Its “Terrific Yield”",
      "id": 138341710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s recent game plan. Cramer had mixed feelings about the stock, as he stated: On the other hand, I worry about Pfizer because while its stock has a terrific yield, I haven’t seen anything of late that would make me feel there’s a new blockbuster […]",
      "url": "https://finnhub.io/api/news?id=46af441c0f628e751bb503aba442b3271c5e5d6e32de5e8600b7c315e5b59c4d"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on PepsiCo’s Recent Rally: “Maybe Something’s Going On”",
    "summary": "PepsiCo, Inc. (NASDAQ:PEP) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted the company’s snack division struggling due to GLP-1 drugs, as he remarked: Now, Tuesday’s filled with high-profile companies like PepsiCo, Merck, and Pfizer in the morning. I worry about PepsiCo because of its snack division, Frito-Lay. It’s struggling, a […]",
    "url": "https://finnhub.io/api/news?id=8373b07b1aa95d4bd5e8c6df932127c629b16d41c1c9c71921b9b8ba86f7d7bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121438,
      "headline": "Jim Cramer on PepsiCo’s Recent Rally: “Maybe Something’s Going On”",
      "id": 138341662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PepsiCo, Inc. (NASDAQ:PEP) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted the company’s snack division struggling due to GLP-1 drugs, as he remarked: Now, Tuesday’s filled with high-profile companies like PepsiCo, Merck, and Pfizer in the morning. I worry about PepsiCo because of its snack division, Frito-Lay. It’s struggling, a […]",
      "url": "https://finnhub.io/api/news?id=8373b07b1aa95d4bd5e8c6df932127c629b16d41c1c9c71921b9b8ba86f7d7bd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand",
    "summary": "Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.",
    "url": "https://finnhub.io/api/news?id=518a4d7be010e6df2c77124e3511c1a8010da3b49e4736e7f6f0e6e9d55e1c20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121260,
      "headline": "Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand",
      "id": 138341737,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.",
      "url": "https://finnhub.io/api/news?id=518a4d7be010e6df2c77124e3511c1a8010da3b49e4736e7f6f0e6e9d55e1c20"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025",
    "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue to be around $61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.2% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=ac21296dc40c6de962dab3819bd0608604e4657d5dad1f7957ada07d047c9198",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121180,
      "headline": "Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025",
      "id": 138341738,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue to be around $61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.2% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=ac21296dc40c6de962dab3819bd0608604e4657d5dad1f7957ada07d047c9198"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings",
    "summary": "US equity futures were mostly pointing higher on Tuesday as traders await a fresh batch of corporate",
    "url": "https://finnhub.io/api/news?id=a4b55d3dfcdc527e15b9028fa2e3c93b8426e666df2a78822f6203e6d77b68b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120977,
      "headline": "Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings",
      "id": 138341612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US equity futures were mostly pointing higher on Tuesday as traders await a fresh batch of corporate",
      "url": "https://finnhub.io/api/news?id=a4b55d3dfcdc527e15b9028fa2e3c93b8426e666df2a78822f6203e6d77b68b3"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Pfizer (PFE) Valuation After Recent Share Price Rebound And Oncology Expansion",
    "summary": "What Pfizer’s recent performance tells you right now Pfizer (PFE) has drawn fresh attention after a period in which the share price has moved higher over the past week, month and past 3 months, putting recent returns in clearer focus for investors. See our latest analysis for Pfizer. That recent 1 month share price return of 5.88% and 3 month share price return of 9.71% sit against a 1 year total shareholder return of 9.14%. The 3 year total shareholder return of a 26.99% decline shows that...",
    "url": "https://finnhub.io/api/news?id=f9a20121f9d9ea4c9728f4b2fca68b5496ab80a2027446f37e1af536d4064e65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120609,
      "headline": "Assessing Pfizer (PFE) Valuation After Recent Share Price Rebound And Oncology Expansion",
      "id": 138341740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "What Pfizer’s recent performance tells you right now Pfizer (PFE) has drawn fresh attention after a period in which the share price has moved higher over the past week, month and past 3 months, putting recent returns in clearer focus for investors. See our latest analysis for Pfizer. That recent 1 month share price return of 5.88% and 3 month share price return of 9.71% sit against a 1 year total shareholder return of 9.14%. The 3 year total shareholder return of a 26.99% decline shows that...",
      "url": "https://finnhub.io/api/news?id=f9a20121f9d9ea4c9728f4b2fca68b5496ab80a2027446f37e1af536d4064e65"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer beats fourth-quarter profit estimates on strong drug demand",
    "summary": "Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter profit above Wall Street estimates, as sustained demand for older drugs such as blood thinner Eliquis helped offset fading sales of its COVID",
    "url": "https://finnhub.io/api/news?id=c4c40b8e943f1c62f2f7923ba5833353a9681cacf8866475a7bff0ca9dc0acaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120058,
      "headline": "Pfizer beats fourth-quarter profit estimates on strong drug demand",
      "id": 138341741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter profit above Wall Street estimates, as sustained demand for older drugs such as blood thinner Eliquis helped offset fading sales of its COVID",
      "url": "https://finnhub.io/api/news?id=c4c40b8e943f1c62f2f7923ba5833353a9681cacf8866475a7bff0ca9dc0acaa"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever",
    "summary": "Pfizer Inc. beat Q4/FY2025 estimates, but COVID sales fell. Click for this updated look at PFE stock post earnings and why I am neutral on its prospects.",
    "url": "https://finnhub.io/api/news?id=1ba0e35147816a7fe3b6cddaf33082757422ebe14ba34e1d314444df3cd94828",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770119770,
      "headline": "Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever",
      "id": 138343435,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1791232366/image_1791232366.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. beat Q4/FY2025 estimates, but COVID sales fell. Click for this updated look at PFE stock post earnings and why I am neutral on its prospects.",
      "url": "https://finnhub.io/api/news?id=1ba0e35147816a7fe3b6cddaf33082757422ebe14ba34e1d314444df3cd94828"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Q4 Earnings Snapshot",
    "summary": "NEW YORK (AP) — Pfizer Inc. PFE) on Tuesday reported a loss of $1.65 billion in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 29 cents.",
    "url": "https://finnhub.io/api/news?id=8bc28164696eb7c1cb1a68153bb3f2ef4ba0e99d783871dae78a1d4d1fb7d85b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770119607,
      "headline": "Pfizer: Q4 Earnings Snapshot",
      "id": 138340796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK (AP) — Pfizer Inc. PFE) on Tuesday reported a loss of $1.65 billion in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 29 cents.",
      "url": "https://finnhub.io/api/news?id=8bc28164696eb7c1cb1a68153bb3f2ef4ba0e99d783871dae78a1d4d1fb7d85b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance",
    "summary": "NEW YORK, February 03, 2026--PFE Q4 2025 Earnings Release",
    "url": "https://finnhub.io/api/news?id=ed11c0684b349d48c0606a4a425bb6e522510b5e2ac5f2f8d63e5371bf0050fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770119100,
      "headline": "Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance",
      "id": 138340797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, February 03, 2026--PFE Q4 2025 Earnings Release",
      "url": "https://finnhub.io/api/news?id=ed11c0684b349d48c0606a4a425bb6e522510b5e2ac5f2f8d63e5371bf0050fa"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial",
    "summary": "NEW YORK, February 03, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives:",
    "url": "https://finnhub.io/api/news?id=0e8b0a9d94c2a58bc725d48ffad88ba1062ad12e834af27bfe81be73b9108724",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770118800,
      "headline": "Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial",
      "id": 138340798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, February 03, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives:",
      "url": "https://finnhub.io/api/news?id=0e8b0a9d94c2a58bc725d48ffad88ba1062ad12e834af27bfe81be73b9108724"
    }
  },
  {
    "ts": null,
    "headline": "Tech Bulls Rule Equities Pre-Bell; Asia Surges, Europe Gains",
    "summary": "Wall Street futures pointed moderately higher pre-bell Tuesday, following record-breaking rallies ov",
    "url": "https://finnhub.io/api/news?id=51b49704d7ea7ffbddbd1ebfa51c0196c13b7d823b3098096d13e996a2b29c33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770117643,
      "headline": "Tech Bulls Rule Equities Pre-Bell; Asia Surges, Europe Gains",
      "id": 138340741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wall Street futures pointed moderately higher pre-bell Tuesday, following record-breaking rallies ov",
      "url": "https://finnhub.io/api/news?id=51b49704d7ea7ffbddbd1ebfa51c0196c13b7d823b3098096d13e996a2b29c33"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Today’s Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, and More",
    "summary": "Stock futures were rising Tuesday as Palantir’s strong earnings injected renewed optimism around the artificial-intelligence trade.  Palantir Technologies  jumped 10% in premarket trading after the company, which sells artificial-intelligence software to manage and analyze large amounts of data, reported better-than expected fourth-quarter adjusted earnings.  Revenue jumped 70% from a year earlier to a record $1.41 billion on strong demand for its AI technology.",
    "url": "https://finnhub.io/api/news?id=05e315ff42909f414aaf1b2be1483a82fec257f9218cec2501d4538edd3a8ce0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770114300,
      "headline": "These Stocks Are Today’s Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, and More",
      "id": 138340729,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stock futures were rising Tuesday as Palantir’s strong earnings injected renewed optimism around the artificial-intelligence trade.  Palantir Technologies  jumped 10% in premarket trading after the company, which sells artificial-intelligence software to manage and analyze large amounts of data, reported better-than expected fourth-quarter adjusted earnings.  Revenue jumped 70% from a year earlier to a record $1.41 billion on strong demand for its AI technology.",
      "url": "https://finnhub.io/api/news?id=05e315ff42909f414aaf1b2be1483a82fec257f9218cec2501d4538edd3a8ce0"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Maintains Neutral on Pfizer (PFE) Amid Rising Margin Pressure",
    "summary": "Pfizer Inc. (NYSE:PFE) ranks among the stocks with the lowest forward PE ratios. On January 23, Goldman Sachs reaffirmed its Neutral rating and $26 price target on Pfizer Inc. (NYSE:PFE), citing the pharma giant’s key hurdles. Pfizer is facing the first of three years of rising patent-cliff strain on its profit margins, as its business […]",
    "url": "https://finnhub.io/api/news?id=3907c2b2423987e7b93a1e7d8971132010795e392f068e997ed1af61dc364fc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770113521,
      "headline": "Goldman Sachs Maintains Neutral on Pfizer (PFE) Amid Rising Margin Pressure",
      "id": 138340801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) ranks among the stocks with the lowest forward PE ratios. On January 23, Goldman Sachs reaffirmed its Neutral rating and $26 price target on Pfizer Inc. (NYSE:PFE), citing the pharma giant’s key hurdles. Pfizer is facing the first of three years of rising patent-cliff strain on its profit margins, as its business […]",
      "url": "https://finnhub.io/api/news?id=3907c2b2423987e7b93a1e7d8971132010795e392f068e997ed1af61dc364fc5"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Tuesday: Palantir, Teradyne, AMD",
    "summary": "↗️ Palantir (PLTR): The data company reported higher-than-expected earnings, as strong demand for its AI technology fueled another quarter of record revenue. Palantir stock jumped 5% in offhours trading.",
    "url": "https://finnhub.io/api/news?id=bbb73c04ae117f7d0e8bac7e16b4b5afa0cb17be2bc8db6eb2f78e47c9014699",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770107948,
      "headline": "Stocks to Watch Tuesday: Palantir, Teradyne, AMD",
      "id": 138340028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "↗️ Palantir (PLTR): The data company reported higher-than-expected earnings, as strong demand for its AI technology fueled another quarter of record revenue. Palantir stock jumped 5% in offhours trading.",
      "url": "https://finnhub.io/api/news?id=bbb73c04ae117f7d0e8bac7e16b4b5afa0cb17be2bc8db6eb2f78e47c9014699"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways",
    "summary": "Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.",
    "url": "https://finnhub.io/api/news?id=60b6d1c420895350e8a898097fdcee889bc3b42fc09a26986ca92b62e75da697",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770106900,
      "headline": "Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways",
      "id": 138343647,
      "image": "https://image.cnbcfm.com/api/v1/image/108260670-17701243561770124353-43828552119-1080pnbcnews.jpg?v=1770124355&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.",
      "url": "https://finnhub.io/api/news?id=60b6d1c420895350e8a898097fdcee889bc3b42fc09a26986ca92b62e75da697"
    }
  },
  {
    "ts": null,
    "headline": "The xAI-SpaceX merger, Palantir earnings, China's frowning horses and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=6368705e46c91a048d8a8e14b39b2c8503bb3343fc3e873fcccc1b1bd0b9da69",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770106360,
      "headline": "The xAI-SpaceX merger, Palantir earnings, China's frowning horses and more in Morning Squawk",
      "id": 138343473,
      "image": "https://image.cnbcfm.com/api/v1/image/108255762-17690962602026-01-22t153714z_1035611969_rc2f6jatc4xw_rtrmadp_0_davos-meeting.jpeg?v=1769096274&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=6368705e46c91a048d8a8e14b39b2c8503bb3343fc3e873fcccc1b1bd0b9da69"
    }
  },
  {
    "ts": null,
    "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
    "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
    "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770105706,
      "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
      "id": 138340001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
      "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more",
    "summary": "These are the stocks posting the largest moves in early trading.",
    "url": "https://finnhub.io/api/news?id=93b8f976d9a2241660827621db63fb76a4411cbc275570ea4d44a48180172444",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770103268,
      "headline": "Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more",
      "id": 138343620,
      "image": "https://image.cnbcfm.com/api/v1/image/108241417-1765569784249-gettyimages-2228106182-raa-palantir250806_npd31.jpeg?v=1770120724&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "These are the stocks posting the largest moves in early trading. ",
      "url": "https://finnhub.io/api/news?id=93b8f976d9a2241660827621db63fb76a4411cbc275570ea4d44a48180172444"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook",
    "summary": "CNBC's Becky Quick reports on the company's quarterly earnings results.",
    "url": "https://finnhub.io/api/news?id=e2fe5cabffdd376cf2a52b6171fca7144111e863974557d267ad071fb767b752",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770103127,
      "headline": "Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook",
      "id": 138343705,
      "image": "https://image.cnbcfm.com/api/v1/image/108260635-17701206121770120610-43827821244-1080pnbcnews.jpg?v=1770120612&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "CNBC's Becky Quick reports on the company's quarterly earnings results.",
      "url": "https://finnhub.io/api/news?id=e2fe5cabffdd376cf2a52b6171fca7144111e863974557d267ad071fb767b752"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial",
    "summary": "The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.",
    "url": "https://finnhub.io/api/news?id=47e093d0159af6de77cf8251abecb9a741e175f28d7c0be878bd717388a257ec",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770103115,
      "headline": "Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial",
      "id": 138343604,
      "image": "https://image.cnbcfm.com/api/v1/image/108218653-1761752333854-gettyimages-2243676983-299665final.jpeg?v=1770120637&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy. ",
      "url": "https://finnhub.io/api/news?id=47e093d0159af6de77cf8251abecb9a741e175f28d7c0be878bd717388a257ec"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook",
    "summary": "The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.",
    "url": "https://finnhub.io/api/news?id=bf7b78f2e80334906ac90ac8f58af7c981bfd9ef4722b91a5182c6782832c92a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770101851,
      "headline": "Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook ",
      "id": 138343707,
      "image": "https://image.cnbcfm.com/api/v1/image/108254867-1769002498225-QjhBpZKA.jpg?v=1769013313&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December. ",
      "url": "https://finnhub.io/api/news?id=bf7b78f2e80334906ac90ac8f58af7c981bfd9ef4722b91a5182c6782832c92a"
    }
  },
  {
    "ts": null,
    "headline": "C4 Therapeutics, Inc. (CCCC): A Bull Case Theory",
    "summary": "We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.’s share was trading at $1.9600 as of January 29th. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein […]",
    "url": "https://finnhub.io/api/news?id=e054ac2ebf2e55b84a09217a33f1d651846cd3461309461c2408fd2d3c07e2c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770083666,
      "headline": "C4 Therapeutics, Inc. (CCCC): A Bull Case Theory",
      "id": 138338023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.’s share was trading at $1.9600 as of January 29th. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein […]",
      "url": "https://finnhub.io/api/news?id=e054ac2ebf2e55b84a09217a33f1d651846cd3461309461c2408fd2d3c07e2c4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story",
    "summary": "Pfizer, NYSE:PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to two infectious disease vaccines. The deal grants Pfizer non-exclusive worldwide rights and immediate control over research, development, and commercialization for these Matrix-M based candidates. Financial terms include an upfront payment, potential future milestone payments, and tiered royalties linked to product sales. Pfizer comes into this agreement...",
    "url": "https://finnhub.io/api/news?id=55532f69d30e14ff1d8c86d3c24f84a03ba2c571e30916378c39bcd881945db5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770080928,
      "headline": "Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story",
      "id": 138338024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer, NYSE:PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to two infectious disease vaccines. The deal grants Pfizer non-exclusive worldwide rights and immediate control over research, development, and commercialization for these Matrix-M based candidates. Financial terms include an upfront payment, potential future milestone payments, and tiered royalties linked to product sales. Pfizer comes into this agreement...",
      "url": "https://finnhub.io/api/news?id=55532f69d30e14ff1d8c86d3c24f84a03ba2c571e30916378c39bcd881945db5"
    }
  },
  {
    "ts": null,
    "headline": "Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Achieve Life Sciences, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc.’s share was trading at $4.18 as of January 30th. Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the […]",
    "url": "https://finnhub.io/api/news?id=506217711d99a029d17b45b302b2d61bb01e0838d754496de1701eeacf8925e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770078745,
      "headline": "Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory",
      "id": 138338025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Achieve Life Sciences, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc.’s share was trading at $4.18 as of January 30th. Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the […]",
      "url": "https://finnhub.io/api/news?id=506217711d99a029d17b45b302b2d61bb01e0838d754496de1701eeacf8925e2"
    }
  },
  {
    "ts": null,
    "headline": "AMD earnings, Netflix-Warner Bros. hearing: What to Watch",
    "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, February 3, including earnings results from companies like Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Pfizer (PFE), and Merck (MRK), and the Senate hearing on Netflix's (NFLX) proposed bid to acquire Warner Bros. Discovery (WBD). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=4ee5d7b830f8532018efe43aa21a2c2c8099f91e6a26d7cd230d9a1df55a74d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770076800,
      "headline": "AMD earnings, Netflix-Warner Bros. hearing: What to Watch",
      "id": 138337318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, February 3, including earnings results from companies like Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Pfizer (PFE), and Merck (MRK), and the Senate hearing on Netflix's (NFLX) proposed bid to acquire Warner Bros. Discovery (WBD). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=4ee5d7b830f8532018efe43aa21a2c2c8099f91e6a26d7cd230d9a1df55a74d4"
    }
  }
]